Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
4
67%
Ph early_phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

5

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 14 (66.7%)
Phase 31 (16.7%)

Trials by Status

completed467%
recruiting117%
withdrawn117%

Recent Activity

1 active trials
Showing 5 of 6
completedphase_1

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

NCT04144257
recruitingphase_1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
completedphase_3

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

NCT04510220
withdrawnphase_1

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

NCT03983252
completedearly_phase_1

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04144257Phase 1

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

Completed
NCT02649985Phase 1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Recruiting
NCT04510220Phase 3

9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Completed
NCT03983252Phase 1

Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

Withdrawn
NCT04616456Early Phase 1

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Completed
NCT03033680Phase 1

Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6